A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.
Publication
, Journal Article
Khanani, AM; Vajzovic, L; Bakall, B; Chavali, VRM; Qamar, H
Published in: Eye (Lond)
February 2026
Duke Scholars
Published In
Eye (Lond)
DOI
EISSN
1476-5454
Publication Date
February 2026
Volume
40
Issue
3
Start / End Page
429 / 430
Location
England
Related Subject Headings
- Ophthalmology & Optometry
- 3212 Ophthalmology and optometry
- 3204 Immunology
- 1113 Opthalmology and Optometry
- 1107 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Khanani, A. M., Vajzovic, L., Bakall, B., Chavali, V. R. M., & Qamar, H. (2026). A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights. Eye (Lond), 40(3), 429–430. https://doi.org/10.1038/s41433-025-04202-5
Khanani, Arshad M., Lejla Vajzovic, Benjamin Bakall, Venkata Ramana Murthy Chavali, and Huma Qamar. “A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.” Eye (Lond) 40, no. 3 (February 2026): 429–30. https://doi.org/10.1038/s41433-025-04202-5.
Khanani AM, Vajzovic L, Bakall B, Chavali VRM, Qamar H. A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights. Eye (Lond). 2026 Feb;40(3):429–30.
Khanani, Arshad M., et al. “A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.” Eye (Lond), vol. 40, no. 3, Feb. 2026, pp. 429–30. Pubmed, doi:10.1038/s41433-025-04202-5.
Khanani AM, Vajzovic L, Bakall B, Chavali VRM, Qamar H. A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights. Eye (Lond). 2026 Feb;40(3):429–430.
Published In
Eye (Lond)
DOI
EISSN
1476-5454
Publication Date
February 2026
Volume
40
Issue
3
Start / End Page
429 / 430
Location
England
Related Subject Headings
- Ophthalmology & Optometry
- 3212 Ophthalmology and optometry
- 3204 Immunology
- 1113 Opthalmology and Optometry
- 1107 Immunology
- 1103 Clinical Sciences